Vol. 5 Issue 2 (2012)

Обложка журнала

PDF downloadDownload the whole Issue

ORIGINAL ARTICLES

Significance of heart injury biomarker (troponin I, heart-type fatty acid binding protein) in patient with acute exacerbations of COPD. G.E. Baimakanova, S.N. Avdeyev P.5

Possible mechanisms of thyroid gland pathology influence on bronchial asthma course. I.A. Кamaeva, N.L. Shaporova P.15

Organization of antituberculous treatment for the mental patients. A.M. Kuklina P.19

The influence of comlex vaccination against pneumococcus, haemophilus influenzae type B infections and influenza in the clinical course of chronic obstructive pulmonary disease. A.D. Protasov, A.A. Ryzhov, A.V. Zhestkov, M.P. Kostinov P.22

Challenge tests in clinical diagnostics of bronchial asthma. O.V. Skorokhodkina, A.V. Luntsov P.24

Comment on the article «Bronhomotornye tests in clinical diagnosis of asthma». N.M. Nenasheva P.29

Active case finding of chronic nonspecific lung diseases (CNLD) by screening K.I. Soloviev, O.V. Korovina P.30

Influence of non-medication methods of pneumonia treatment on the concentration of trace elements in blood serum and microcirculation. N.B. Amirov, A.A. Vizel, M.V. Potapova P.35

HELP FOR PRACTITIONER

Role of whole body plethysmography in practice of general practitioner. R.I. Shaymuratov, O.Yu. Mikhoparova, E.B. Frolova P.40

LITERATURE REVIEW

Update on current therapy of asthma. Majid Sadigh, Jaime P. Moskowitz, R.I. Shaymuratov, He Zhang, A.A. Vizel P.48

Sarcoidosis: the possibility of spontaneous remission. I.Yu. Vizel P.54

Acute lung injury: the definition, pathogenesis, animal models and the role of mesenchymal stem cells in experimental treatment. K.S. Voytkovskaya, A.L. Cherniaev P.60

In memory of Nikolay Grigoryevich Sokolov A.A. Vizel P.68

_____

ORIGINAL ARTICLES

PDF downloadSignificance of heart injury biomarker (troponin I, heart-type fatty acid binding protein) in patient with acute exacerbations of COPD

Gulsara E. Baimakanova, Ph.D., Senior Researcher, laboratory of intensive care and respiratory failure e FGu «Institute of Pulmonology» FmBA of Russia, moscow, Russia, st.11th Park, 32, Clinical Hospital № 57, building 4, tel/fax 8(495)465-74-15, e-mail: gulsara.bai@mail.ru

Sergey N. Avdeev, MD, professor, head of clinical department FGu «Institute of Pulmonology» FmBA of Russia, 105 077, moscow, Russia, st.11th Park, 32, Clinical Hospital № 57, building 4, tel/fax 8(495)465-52-64, e-mail: serg_avdeev@list.ru

Abstact. To evaluate the diagnostic and prognostic value of heart injury biomarker (Heart-type fatty acid binding protein, Troponin I) in patients with acute exacerbations of COPD (AECOPD). Prospective observational study. We enrolled 80 hospitalized patients with AECOPD [male 67, female 13, age (64,2±7,8) years, BMI (25,8±8,8) kg/m2]. These patients underwent a complex diagnostic investigation including chest radiography, pulmonary function tests, echocardiography and measurement of serum Tn I (Biomerica), H-FABP (Hycult Biotech) and BNP-fragment (Biomedica). The main causes of AECOPD were purulent bronchitis (43,7%), pneumonia (32,5%), acute decompensation of chronic heart failure (ADCHF) (12,5%) and acute myocardial infarction (AMI) (11,3%). BNP-fragment levels were significantly higher in patients with pneumonia (p=0,007), ADCHF (p=0,002), AMI (p=0,012) than in patients with purulent bronchitis. There were no significant differences between patients with pneumonia and ADCHF (p=0,128), pneumonia and AMI (p=0,651). Patients with AMI had the higher levels of H-FABP than patients with purulent bronchitis (p=0,003), there were no significant differences between other groups of patients. A positive Tn I test was defined as >0,5 ng/mL and its levels were increased in 21,3% of cases, but there were no significant differences between patients’ groups. The ROC curve (AUC) for the prediction of hospital mortality of all causes increased for BNP-fragment (AUC presentation: 0,827; 95%CI: 0,729—0,626, p<0,0001, sensitivity 0,789, specificity 0,787) and for H-FABP (AUC presentation: 0,809; 95%CI: 0,673—0,945, p<0,0001, sensitivity 0,737, specificity 0,869). Survival was worse in patients with elevated Tn I >0,5 ng/mL compared to patients with levels of Tn I<0,5 ng/mL (log-rank test, p<0,0001). Conclusions: In patients with AECOPD levels of Tn I and H-FABP were increased without coronary heart damage and were strong predictors of hospital mortality from all causes of AECOPD.

Key words: COPD, exacerbations, biomarkers.

 

 References

  1. Camilli AE, Robbins DR, Lebowitz MD. Death certificate reporting of confirmed airways obstructive disease. Am J Epidemiol 1991; 133: 795–800.
  2. JanssensJP, Herrmann F, MacGee W, Michel JP. Cause of death in older patients with anatomo-pathological evidence of chronic bronchitis or emphysema: a case-control study based on autopsy findings. J Am Geriatr Soc 2001; 49: 571–576.
  3. Rutten FH, Moons KG, Cramer MJ, et al. Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross-sectional diagnostic study. BMJ 2005; 331: 1379.
  4. Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet 1996; 348: 567–572.
  5. Engstrom G, Wollmer P, Hedblad B, Juul-Mo¨ ller S, Valind S, Janzon L. Occurrence and prognostic significance of ventricular arrhythmia is related to pulmonary function: a study from “men born in 1914”, Malmo¨, Sweden. Circulation 2001; 103: 3086–3091.
  6. Huiart L, Ernst P, Ranouil X, et al. Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur Respir J 2005; 25: 634-639.
  7. Rosengren A, Wilhelmsen L. Respiratory symptoms and long-term risk of death from cardiovascular disease, cancer and other causes in Swedish men. Int J Epidemiol 1998; 27: 962-969.
  8. Pingleton SK. Complications of acute respiratory failure. Am Rev Respir Dis 1988; 137: 1463–1493.
  9. Render ML, Weinstein AS, Blaustein AS. Left ventricular dysfunction in deteriorating patients with chronic obstructive pulmonary disease. Chest 1995; 107: 162–168.
  10. Parmacek MS, Solaro RJ. Biology of the troponin complex in cardiac myocytes. Prog Cardiovasc Dis 2004; 47(3): 159–76.
  11. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. J Am Coll Cardiol 2007; 50(22): 2174-95.
  12. Adams JE III, Bodor G, Davila-Roman V, et al. Cardiac troponin I. A marker with high specificity for cardiac injury. Circulation 1993; 88 (1): 101–6.
  13. Missov E, Calzolari C, Pau B. Circulating cardiac troponin I in severe congestive heart failure. Circulation. 1997; 96: 2953-8.
  14. Meyer T, Binder L, Hruska N, Luthe H, Buchwald AB. Cardiac troponin I elevation in acute pulmonary embolism is associated with right ventricular dysfunction. J Am Coll Cardiol. 2000; 36: 1632-6.
  15. Baillard C, Boussarssar M, Fosse JP, et al. Cardiac troponin I in patients with severe exacerbation of chronic obstructive pulmonary disease. Intensive Care Med. 2003; 29: 584-9.
  16. King DA, Codish S, Novack V, et al. The role of cardiac troponin I as a prognosticator in critically ill medical patients: a prospective observational cohort study. Crit Care 2005; 9(4): 31.
  17. Kollef MH, Ladenson JH, Eisenberg PR. Clinically recognized cardiac dysfunction: an independent determinant of mortality among critically ill patients. Chest 1997; 111(5): 1340–7.
  18. Noble J, Reid A, Jordan L, et al. Troponin I and myocardial injury in the ICU. Br J Anaesth 1999; 82: 41–6.
  19. Relos RP, Hasinoff IK, Beilman GJ. Moderately elevated serum troponin concentrations are associated with increased morbidity and mortality rates in surgical intensive care unit patients. Crit Care Med 2003; 31(11): 2598–603.
  20. Turley AJ, Gedney JA. Role of cardiac troponin as a prognosticator in critically ill patients. Crit Care 2005; 9(6): E30.
  21. Wright RS, Williams BA, Cramner H, et al. Elevations of cardiac troponin I are associated with increased short-term mortality in noncardiac critically ill emergency department patients. Am J Cardiol 2002; 90(6): 634–6.
  22. Babuin L, Vasile VC, Rio Perez JA, et al. Elevated cardiac troponin is an independent risk factor for short- and long-term mortality in medical intensive care unit patients. Crit Care Med 2008; 36(3): 759–65.
  23. Jaffe AS, Ravkilde J, Roberts R, et al. It’s time for a change to a troponin standard. Circulation 2000; 102: 1216–20.
  24. Pelsers MM, Hermens WT, Glatz JF. Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta 2005, 352: 15-35.
  25. Chan CP, Sum KW, Cheung KY, et al. Development of a quantitative lateral-flow assay for rapid detection of fatty acid-binding protein. J Immunol Methods 2003; 279(1/2): 91–100.
  26. Panteghini M. Role and importance of biochemical markers in clinical cardiology. Eur Heart J 2004; 25: 1187–96.
  27. Mad P, Domanovits H, Fazelnia C, et al. Human heart-type fatty-acid-binding protein as a point-of-care test in the early diagnosis of acute myocardial infarction. QJM 2007; 100: 203–210.
  28. Nakata T, Hashimoto A, Hase M, et al. Human heart-type fatty acid-binding protein as an early diagnostic and prognostic marker in acute coronary syndrome. Cardiology 2003; 99: 96-104.
  29. Okamoto F, Sohmiya K, Ohkaru Y, et al. Human heart-type cytoplasmic fatty acid-binding protein (H-FABP) for the diagnosis of acute myocardial infarction. Clinical evaluation of H-FABP in comparison with myoglobin and creatine kinase isoenzyme MB. Clin Chem Lab Med 2000; 38: 231-238.
  30. Glatz JF, van Bilsen M, Paulussen RJ, et al. Release of fatty acid-binding protein from isolated rat heart subjected to ischemia and reperfusion or to the calcium paradox. Biochim Biophys Acta 1988; 961 (1): 148–52.
  31. Ishii J, Wang JH, Naruse H, et al. Serum concentrations of myoglobin vs human heart-type cytoplasmic fatty acidbinding protein in early detection of acute myocardial infarction. Clin Chem 1997; 43: 1372–8.
  32. Ghani F, Wu AH, Graff L, et al. Role of heart-type fatty acidbinding protein in early detection of acute myocardial infarction. Clin Chem 2000; 46:718–19.
  33. Alansari SE, Croal BL Diagnostic value of heart fatty acid binding protein and myoglobin in patients admitted with chest pain. Ann Clin Biochem 2004; 41: 391–6.
  34. Niizeki T, Takeishi Y, Arimoto T, et al. Persistently increased serum concentration of heart-type fatty-acidbinding protein predicts adverse clinical outcomes in patients with chronic heart failure. Circ J 2008; 72: 109–114.
  35. Puls M, Dellas C, Lankeit M, et al. Heart-type fatty acid binding protein permits early risk stratification of pulmonary embolism. Eur Heart J 2007; 28: 224–229.
  36. Kaczynska A, Pelsers MM, Bochowicz A, et al. Plasma heart-type fatty acid binding protein is superior to troponin and myoglobin for rapid risk stratification in acute pulmonary embolism. Clinica Chimica Acta 2006; 371: 117–123.
  37. Oktay B, Ardic S.  Is heart type fatty acid binding protein a marker of cardiac damage in patients with acute attacks of chronic obstructive pulmonary disease? Eur Respir J 2009; Р3111; 103s
  38. Seyhan EC, Önür I, Sökücü S, et al., Relation of troponin and hert type fatty acid protein (H-FABP) levels to echocardiographic and cardiac infarction injury score (CIS) with patients with prespiratory insufficiency due to COPD attack. Eur Respir J 2009; Р695; 123s
  39. Brekke PH, Omland T, Holmedal SH, et al. Troponin T elevation and long-term mortality after chronic obstructive pulmonary disease exacerbation. Eur Respir J 2008; 31: 563–70.
  40. Martins CS., Rodrigues MJO, Miranda VP,. Nunes JPL Prognostic value of cardiac troponin I in patients with COPD acute exacerbation. The Netherlands Journal of Medicine 2009; 67 (10): 341-349
  41. Chang CL, Robinson SC, Mills GD et al., Biochemical Markers of Cardiac Dysfunction Predict Mortality in Acute Exacerbations of COPD. Thorax. 2011; 66(9): 764-768. 
  42. Global Initiative for Chronic Obstructive Lung Disease GOLD. Global Strategy for the Diagnosis, Management, and Preventionof Chronic Obstructive Pulmonary Disease. 2009. http://www.goldcopd.com (accessed 27 Jun 2010).
  43. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196–204.
  44. Quanier PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Eur Respir J 1993; 6(Suppl. I6): 5-40.
  45. Swedberg K, Cleland J, Dargie H, et al. The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J 2005; 26: 1115–40.
  46. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001; 37: 386–391
  47. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Circulation 2007; 27; 116: 26-34
  48. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J 2006; 28: 1245–1257
  49. Holguin F, Folch E, Redd SC, et al. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979–2001. Chest 2005; 128: 2005–11.
  50. Korff S, Katus HA, Giannitsis E. Differential diagnosis of elevated troponins. Heart 2006; 92: 987–993.
  51. Torbicki A, Kurzyna M, Kuca P, et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 2003; 108: 844–848.
  52. Barnes PJ. Chronic obstructive fulmonary disease. N Engl J Med 2000; 343: 269–280.
  53. Wouters EFM. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 26–33.
  54. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685–1695.
  55. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet 2007; 370: 797–9.
  56. Donaldson GC, Hurst JR, Smith CJ, et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010; 137: 1091–7.
  57. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996; 335: 1342–1349.
  58. Jeremias A, Gibson M. Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. Ann Intern Med. 2005; 142: 786-91
  59. Higgins JP, Higgins JA. Elevation of cardiac troponin I indicates more than myocardial ischemia. Clin Invest Med. 2003; 26: 133-47.
  60. Meyer T, Binder L, Hruska N, Luthe H, Buchwald AB. Cardiac troponin I elevation in acute pulmonary embolism is associated with right ventricular dysfunction. J Am Coll Cardiol 2000; 36: 1632–1636.
  61. Mahajan N, Mehta Y, Rose M, Shani J, Lichstein E. Elevated troponin level is not synonymous with myocardial infarction. Int J Cardiol 2006; 111: 442–449.
  62. Nunes JPL, Macedo F. An analytical triad for the diagnosis of pulmonary embolism. Cardiology. 2000;.94:.264.
  63. Hessel MHM, Atsma DE, van der Valk EJM, Bax WH, Schalij MJ, van der Laarse A. Release of cardiac troponin I from viable cardiomyocytes is mediated by integrin stimulation. Pflugers Arch Eur J Physiol. 2008; 455: 979-86.
  64. Feng J, Schaus BJ, Fallavollita JA, Lee TC, Canty JM. Preload induces troponin I degradation independently of myocardial ischemia. Circulation. 2001; 103: 2035-7.
  65. Peacock WF, De Marco T, Fonarow GC, et al. Cardiac troponin I and outcome in acute heart failure. N Engl J Med. 2008;.358:.2117-26.
  66. Abroug F, Ouanes-Besbes L, Nciri N, et al. Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disease: diagnostic performance of cardiac biomarkers. Am J Respir Crit Care Med 2006;.174:.990–6.
  67. Le Jemtel T, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2007; 49(2): 171-80.
  68. Stolz D., Breidthardt N., Christ-Crain M., et al. Use of B-Type Natriuretic Peptide in the Risk Stratification of Acute Exacerbations of COPD. Chest 2008; 133(5): 1088-1094.
  69. Seino Y, Ogata K, Takano T, et al. Use of a whole blood rapid panel test for heart-type fatty acid-binding protein in patients with acute chest pain: comparison with rapid troponin T and myoglobin tests. Am J Med 2003; 115(3): 185–90.
  70. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009; 361(9): 858–67.
  71. Valle HA, Riesgo LG, Bel MS, et al. Clinical assessment of heart-type fatty acid binding protein in early diagnosis of acute coronary syndrome. Eur J Emerg Med 2008; 15(3): 140–4.
  72. Haltern G, Peiniger S, Bufe A, et al. Comparison of usefulness of heart-type fatty acid binding protein versus cardiac troponin T for diagnosis of acute myocardial infarction. Am J Cardiol 2010; 105(1): 1–9.
  73. McCann CJ, Glover BM, Menown IB, et al. Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T. Eur Heart J 2008; 29(23): 2843–50.
  74. O’Donoghue M, de Lemos JA, Morrow DA, et al. Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation 2006; 114(6): 550–7.
  75. Kilcullen N, Viswanathan K, Das R, et al. Heart-type fatty acid-binding protein predicts long-term mortality after acute coronary syndrome and identifies high-risk patients across the range of troponin values. J Am Coll Cardiol 2007; 50: 2061–2067.
  76. Vuilleumier N, Le Gal G, Verschuren F, et al. Cardiac biomarkers for risk stratification in non-massive pulmonary embolism: a multicenter prospective study. J Thromb Haemost 2009; 7: 391–8.
  77. Yan GT, Lin J, Hao XH, et al. Heart-type fatty acid-binding protein is a useful marker for organ dysfunction and leptin alleviates sepsis-induced organ injuries by restraining its tissue levels. Eur J Pharmacol 2009; 616(1–3): 244–50.
  78. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514-1519.
  79. Schunemann HJ, Dorn J, Grant BJ, Winkelstein W Jr., Trevisan M. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest 2000; 118: 656–664.
  80. Bang KM, Gergen PJ, Kramer R, et al. The effect of pulmonary impairment on all-cause mortality in a national cohort. Chest 1993; 103: 536–540.
  81. Gan WQ, Man SFP, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and meta-analysis. Thorax 2004; 59: 574–580.
  82. Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000; 84: 210–215.
  83. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the production of coronary heart disease. N Engl J Med 2004; 350:1387–1397.

 

 

PDF downloadPossible mechanisms of thyroid gland pathology influence on bronchial asthma course

Irina A. Кamaeva, mD, assistant professor at General Practice Department of St. Petersburg Pavlov State medical university, e-mail: kkami@inbox.ru

Natalia L. Shaporova, MD, PhD, DSc, professor, head of the General Practice Department of St. Petersburg Pavlov State medical university, e-mail: shapnl@mail.ru

Abstract. To reveal possible mechanisms of thyroid gland pathology influence on bronchial asthma (BA) course 60 patients have been examined in 5 equal groups: BA; hypothyroidism; hyperthyroidism; BA + hypothyroidism; BA+ hyperthyroidism. Serum IgE and IgG levels were assessed. Spirometry was performed. Between BA + hypothyroidism and BA groups differences have been revealed in: asthma attack frequency (6,2±0,3, vs. 4,5±0,6; р=0,04); BA remission duration [(8,6±0,9) weeks, vs. (12,1±0,8) weeks; р=0,02]; FEF50 (48,91±3,02, vs. 60,62±2,53; р=0,04) and FEF75 (35,24±1,78, vs. 48,74±1,78; р=0,03). Between BA+ hyperthyroidism and BA groups have been revealed differences: in BA remission duration [(9,3±0,4) weeks, vs. (12,1±0,8) weeks; p=0,03]; in serum IgE levels (266,7±17,3, vs 159,4±3,8; p=0,01).The possible asthma worsening mechanism in BA+ hyperthyroidism group concerns with Th2 excessive stimulation; in BA+hypothyroidism group — concerns with mixedema.

Key words: bronchial asthma, hypothyroidism, hyperthyroidism

 

References

  1. Il'ina O.Ju. Osobennosti razvitija, kliniki i techenija bronhial'noj astmy v sochetanii s patologiej shhitovidnoj zhelezy.: Avtoref. dis... kand. med. nauk. SPb., 2006.-11s.
  2. Popova N.V., Bondar' I.A., Kudelja L.M. Osobennosti bronhial'noj astmy u bol'nyh s pervichnym gipotireozom //Medicina i obrazovanie v Sibiri. – 2010. - № 5. – S.89-92
  3. Semenova N. V. Kliniko-patogeneticheskie aspekty sochetanija bronhial'noj astmy s autoimunnym tireoiditom.: Avtoref. dis... kand. med. nauk. M., 1998., -24s; 77s.
  4. Fedoseev G.B., Trofimov V.I. Bronhial'naja astma. – Sankt-Peterburg: Nordmedizdat, 2006.-308s.
  5. Shubina O.V. Kliniko-immunologicheskie osobennosti techenija bronhial'noj astmy v sochetanii gipotireozom. Avtoref. dis. kand. med. nauk. M., 2010. – 14s.
  6. Guo J., Rapoport B., McLachlan SM. Thyroid peroxidase autoantibodies of IgE class in thyroid autoimmunity // Clin. Immunol. Immunopathol. 82:157-1621997
  7. Manzolli S., Macedo-Soares M.F., Vianna E.O., Sannomiya P. Allergic airway inflammation in hypothyroid rats // J Allergy Clin Immunol. 1999 Sep;104(3 Pt 1):595-600
  8. Roberts C.G., Landenson P.W. Hyothyroidism // Lancet. – 2004. – Vol.363. – P/793-803.
  9. Settipane G.A., Hamolsky M.W. Status asthmaticus associated with hyperthyroidism // Engl Reg Allergy Proc. 1987 Sep-Oct; 8(5):323-6.
  10. Sato A, Takemura Y, Yamada T, Ohtsuka H, Sakai H, Miyahara Y, Aizawa T, Terao A, Onuma S, Junen K, Kanamori A, Nakamura Y, Tejima E, Ito Y, Kamijo K. A possible role of immunoglobulin E in patients with hyperthyroid Graves' disease // J Clin Endocrinol Metab. 1999 Oct; 84(10):3602-5.
  11. Takashi Yamada, Akira Sato, Ichiro Komiya et al. An elevation of Serum Immunoglobulin E Provides a New aspect of Hyperthyroid Graves Disease // The Journal of Clinical Endocrinology & Metabolism 2000 Vol.85, No.8:2775-2778.

 

PDF downloadOrganization of antituberculous treatment for the mental patients

Anna M. Kuklina, psychiatrist, the Naberezhnye Chelny Psychoneurological Dispensary of the Republican Clinical mental Health Center named after V.m. Bekhterev of the ministry of Healthcare of the Republic of Tatarstan. (423812), Russia, Republic of Tatarstan, Naberezhnye Chelny, World, 14, tel. (8552)588-438, 8-960-076-87-43, e-mail: dr.kuklina@mail.ru

Abstract. There has been made an analysis of tuberculosis prevalence rate among the mental patients and antituberculous treatment of this group of patients. The average age of patients suffering from tuberculosis is over 30 years, more often these are patients suffering from schizo-affective psychosis. Mental patients have no somatic complaints. It is revealed that mental patients visit a physician and undergo prescribed medical tests less frequently.

Key words: tuberculosis, schizophrenia, mental patients.

 

References

  1. Baronova O.D. Osobennosti vyjavlenija, klinicheskogo techenija i jeffektivnost' lechenija tuberkuleza legkih u bol'nyh s psihicheskimi zabolevanijami, prozhivajushhih v psihonevrologicheskih internatah: dissertacija kandidata medicinskih nauk, Moskva, 2009.- S155.
  2. Kornilova Z.H., Gjunashjan N.R., Sofronova N.S. Klinika, diagnostika i lechenie vpervye vyjavlennogo tuberkuleza legkih, sochetannogo s psihicheskimi zabolevanijami. // Tuberkulez v Rossii. God 2007: materialy V111 Rossijskogo s#ezda ftiziatrov. – M.:OOO «Ideja», 2007. - S.405.
  3. Med.spravochnik, Amerikanskaja Medicinskaja klinika, Tuberkulez, Sankt-Peterburg,2011,S335.
  4. Nechaeva O.B., Arenskij V.A., Jejsmont N.V. Tuberkulez v psihonevrologicheskih internatah Sverdlovskoj oblasti// Probl.tub. – 1998. -№ 3.- S.19-20.
  5. Prikaz Minzdrava Rossii ot 21.03.2003 № 109 «O Sovershenstvovanii protivotuberkuleznyh meroprijatij v Rossijskoj Federacii»", prilozhenie №7, instrukcija po organizacii dispansernogo nabljudenija i ucheta kontingentov protivotuberkuleznyh meroprijatij.
  6. Jejsmont N.V. Organizacija kompleksnyh protivotuberkuleznyh meroprijatij v stacionarnyh uchrezhdenijah dlitel'nogo prebyvanija: Avtoref. dis. kand.med.nauk. - Moskva. – 2002. S. 3-13.

 

PDF downloadThe influence of comlex vaccination against pneumococcus, haemophilus influenzae type B infections and influenza in the clinical course of chronic obstructive pulmonary disease

Andrey D. Protasov, mD, PhD, Department of microbiology, Immunology and Allergy, Samara State medical university, Samara, tel: 8-927-744-41-26, e-mail: crosss82@mail.ru

Alexey A. Ryzhov, mD, PhD, laboratory of vaccination and immunotherapy of allergic diseases, Research Institute of Vaccines and Serums behalf I.I. mechnikov, moscow, e-mail: vaccine@bk.ru

Alexander V. Zhestkov, mD, PhD, Professor, Head of the chair of microbiology, Immunology and Allergy, Samara State medical university, Samara, tel: (846) 260-33-61, e-mail: zhestkovav@yandex.ru

Mikhail P. Kostinov, mD, PhD, Professor, Head of the laboratory of vaccination and immunotherapy of allergic diseases, Research Institute of Vaccines and Serums behalf I.I. mechnikov, moscow, e-mail: vaccine@bk.ru

Abstract. This article analyzes the clinical effect of combined use of vaccines against Pneumococcal, Haemophilus influenzae type binfections and influenza in patients with chronic obstructive pulmonary disease (COPD) compared with unvaccinated patients. I group — 48 patients with COPD, simultaneously vaccinated against Pneumococcal, Haemophilus influenzae type binfections and influenza [mean age (61,46±1,17) years]. II group — 80 non-vaccinated patients with COPD [mean age (54,65±0,6) years]. In patients with COPD the frequency of exacerbations of the disease decreased by 3,7 times after vaccination, and conducted courses of antimicrobial chemotherapy — 4,3 times.

Key words: vaccination, chronic obstructive pulmonary disease.

 

References

  1. Sinopal'nikov A.I. Infekcionnoe obostrenie hronicheskoj obstruktivnoj bolezni legkih / A.I. Sinopal'nikov, A.G. Romanovskih // Pul'monologija. - 2006. - № 1.
  2. Haitov M.R. Rol' respiratornyh virusov v techenie hronicheskih obstruktivnyh zabolevanij respiratornogo trakta. / M.R. Haitov, V.S. Akimov // Rossijskij respiratornyj zhurnal. – 2005. - № 6. – S. 65-69.
  3. Chuchalin A.G. Hronicheskaja obstruktivnaja bolezn' legkih. Monografija. M.: Izdatel'skij dom «Atmosfera», 2008. – C. 217-221.
  4. Global initiative for chronic obstructive lung disease. National Institutes of Health. – 2009.

 

PDF downloadChallenge tests in clinical diagnostics of bronchial asthma

Olesya V. Skorokhodkina, Doctor of Science, PhD, Professor of Department of Clinical Immunology and Allergology of Kazan State Medical University, Kazan, Russian Federation, pozd-alexandr@rambler.ru.

Alexey V. Luntsov, PhD, allergologist-immunologist of Republican Clinical Hospital, Kazan, Russian Federation, lountsov@rambler.ru.

Abstract. The modern representations about using of challenge tests in clinical diagnostics of bronchial asthma are reflected in the article. Bronchodilatation test and tests directed on revealing of bronchial hyperresponsivness (challenge tests with histamine, metaholine and hypertonic solution of sodium chloride, exercise challenge test) are characterized and their place in diagnostic process is discussed.

Keywords: bronchial asthma, challenge tests, bronchial hyperresponsiveness.

 

References

  1. Baranov V.P. Issledovanie funkcii vneshnego dyhanija / V.P. Baranov, I.G. Kurenkova, V.A. Kazancev, M.A. Haritonov // S.- Peterburg.- «Jelbi-SPb».- 2002.- 302 s.
  2. Global'naja strategija lechenija i profilaktiki bronhial'noj astmy (GINA). Peresmotr 2006 g.
  3. Mizernickij Ju.L., Cyplenkova S.Je. Sovremennye funkcional'nye metody issledovanija v detskoj pul'monologii.- Moskva: NTO im. S.I.Vavilova.- 2007. – 28 s.
  4. Shirjaeva I. S. Klinicheskoe znachenie funkcional'nyh metodov issledovanija pri allergicheskih zabolevanijah u detej  / I. S. Shirjaeva, B. P. Savel'ev, V. S. Reutova i dr. // Pediatrija.- 1999.- № 4. - S. 37-41.
  5. Savel'ev B.P., Shirjaeva I.S. Funkcional'nye parametry sistemy dyhanija u detej i podrostkov. Rukovodstvo dlja vrachej.- M.- 2001.- 230 s.
  6. Coj A.N. Dokazatel'naja medicina v diagnostike i lechenii bronhial'noj astmy / A.N. Coj, V.V. Arhipov, A.G. Chuchalin // Internet-istochnik: www.volgmed.ru/publishing/lv/s/2002/2/lv-2002-2-003.pdf   
  7. Ichinose M. Baseline airway hyperresponsiveness and its reversible component: role of airway inflammation and airway caliber /  M. Ichinose, T. Takahashi, H. Sugiura // European Respiratory Journal.- 2000.- V 15. № 2.- P. 248-253.
  8. Wegner C. D. Chronic models of airway hyperresponsiveness / C. D. Wegner // European Respiratory Review.- 1995.- T. 5.- № 29. - P. 218-223.
  9. Tiffeneau R. From pulmonary allergy to the bronchomotor hyperexcitability of the asthmatic / R. Tiffeneau // Presse Med.- 1959.- V. 21.- №67.- P. 2017-9.
  10. Avital A. Exercise, methacholine, and adenosine 5'-monophosphate challenges in children with asthma: relation to severity of the disease / A. Avital, S. Godfrey, C. Springer // Pediatr. Pulmonol.- 2000.- V. 30.- № 3. P. 207-14.
  11. Souza A.C. Bronchial provocation tests using methacholine, cycle ergometer exercise and free running in children with intermittent asthma / A.C. Souza , C.A. Pereira // J. Pediatr. (Rio. J.).- 2005.- V. 81.- № 1.- P. 65-72.
  12. Standartizacija testov issledovanija legochnoj funkcii // Pul'monologija.– 1993.– Prilozhenie.- S. 140.
  13. Currie G.P. Determinants of airway hyperresponsiveness in mild asthma / G.P. Currie, C.M. Jackson, D.K. Lee, B.J. Lipworth // Ann. Allergy Asthma Immunol.- 2003.- V. 90.- № 5.- P. 560-3.
  14. Hargreave F.E. Airway responsiveness to histamine or methacholine: advances in measurement and interpretation / F.E. Hargreave, P. Sterk, E.C. Adelroth et al. // Respiration.- 1986.- V. 50.- № 2.- P. 72-6.
  15. Sterk P.J. Bronchial hyperresponsiveness today / P.J. Sterk // Respir. Med.- 1993.- V. 87.- P. 27-9.
  16. Connolly M.J. The use of sequential doses of inhaled histamine in the measurement of bronchial responsiveness: cumulative effect and distortion produced by shortening the test protocol / M.J. Connolly, A.J. Avery, E.H. Walters et al. // J. Allergy Clin. Immunol.- 1988.- V. 82.- № 5.- P.863-8.
  17. Higgins B.G. Comparison of histamine and methacholine for use in bronchial challenge tests in community studies / B.G. Higgins, J.R. Britton, S. Chinn et al. // Thorax.- 1988.- V. 43.- № 8.- P. 605-10.
  18. Loror G. Klinicheskaja immunologija i allergologija / G.Loror, T.Fisher, D.Adel'man // (red.) Per. s angl. - M.: Praktika, 2000.
  19. Pattemore P.K. Bronchial hyperresponsiveness and its relationship to asthma in childhood / P.K. Pattemore, S.T. Holgate // Clin. Exp. Allergy.- 1993.- V. 23.- № 11.- P. 886-900.
  20. De Vries K. Reactivity of the bronchial tree to different stimuli / K. de Vries, H. Booy-Nord et al. // Bronches.- 1968.- V. 18.- № 6.- P. 439-52.
  21. Smith C.M. Inhalation provocation tests using nonisotonic aerosols / C.M. Smith , S.D. Anderson //  J. Allergy Clin. Immunol.- 1989.- V. 84.- № 5.- P. 781-90.
  22. Gravelyn T.R. Mediator release in an isolated airway segment in subjects with asthma / T.R. Gravelyn, P.M. Pan, W.L.Eschenbacher // Am. Rev. Respir. Dis.- 1988.- V. 137.- № 3.- P. 641-6.
  23. Clough J.B. Airway response to exercise and methacholine in children with respiratory symptoms / J.B. Clough, S.A. Hutchinson, J.D. Williams et al. // Arch. Dis. Child.- 1991.- V. 66.- № 5.- P. 579-83.
  24. Eliasson A.H. Sensitivity and specificity of bronchial provocation testing. An evaluation of four techniques in exercise-induced bronchospasm / A.H. Eliasson, Y.Y. Phillips, K.R. Rajagopal et al. // Chest.- 1992.- V. 102.- № 2.- P. 347-55.
  25. Kerstjens H.A. Corticosteroid-induced improvement in the PC20 of adenosine monophosphate is more closely associated with reduction in airway inflammation than improvement in the PC20 of methacholine / H.A. Kerstjens, R.J. Meijer, D.M. de Reus et al. //  Am. J. Respir. Crit. Care Med.- 2001.- V. 164.- № 7.- P. 1127-32.
  26. O'Donnell A.E. Exercise-induced airflow obstruction in a healthy military population / A.E. O'Donnell, J. Fling // Chest.- 1993.- V. 103.- № 3.- P. 742-4.
  27. Haby M.M. An exercise challenge for epidemiological studies of childhood asthma: validity and repeatability / M.M. Haby, J.K. Peat, C.M. Mellis et al. // Eur. Respir. J.- 1995.-V. 8.- № 5.- P. 729-36.
  28. Holzer K. Evidence-based management of exercise-induced asthma / K. Holzer, P. Brukner, J. Douglass // Curr. Sports Med. Rep.- 2002.- V. 1.- № 2.- P. 86-92.

 

PDF downloadComment on the article «Bronhomotornye tests in clinical diagnosis of asthma».

N.M. Nenasheva MD, Professor, Department of Clinical Allergology GBOU DPO RMAPO, Moscow

References

  1. Nenasheva N.M. Jetapy diagnostiki bronhial'noj astmy u podrostkov muzhskogo pola. RAZh.-2008;6:19-25
  2. N.M.Nenasheva Klinicheskie fenotipy atopicheskoj bronhial'noj astmy. Palmarium Academic Publishing.-2012.-319c

 

PDF downloadActive case finding of chronic nonspecific lung diseases (CNLD) by screening

Konstantin I. Soloviev, MD, PhD, chief pulmonologist of Novgorod region, head of pulmonology department of Novgorod region clinic, senior lecturer of Therapy chair of the State Educational Institution of Higher Vocational Education "Yaroslav-the-Wise Novgorod State University", Honoured Doctor of the Russian Federation, solovievki@mail.ru.

Oksana V. Korovina, MD, PhD, Professor of pulmonology chair, St. Petersburg Medical Academy of Postgraduate Education.

Abstract. A screening study of 4590 citizens of Novgorod region was performed for establishing risk factors of CNLD, and its influence on prevalence of chronic bronchopulmonary disease. Results: It is established that true incidence of various forms of CNLD exceeds 3.3 times registered. Incidence depends on the prevalence of tobacco smoking habits, exposure to pollutants of industrial dust, chronic nasal infections, respiratory infections, age, and atmospheric pollution.

Keywords: CNLD, prevalence, risk factors for CNLD.

 

 

PDF downloadInfluence of non-medication methods of pneumonia treatment on the concentration of trace elements in blood serum and microcirculation

N.B. Amirov, A.A. Vizel, M.V. Potapova

Abstract. The influence of laserotherapy on blood serum microelements content and microcirculation condition in complex treatment of pneumonia studied. 105 patients with pneumonia observed. Patients were divided into two groups: examination group — 66 patients (persons) received laserotherapy during the medicamentation therapy and check-up group — 35 patients (persons) only medicamentation treatment received. In examination group a certain more significant membrane permeability decrease, iron and chromium blood serum content increase and microcirculation condition improvement at the expense of vascular component is established compared with check-up group. Indicated changes had great correlation degree with laboratory data and external breath function indicators.

Key words: рneumonia, laser therapy, microcirculation and micro-elements, the permeability of cell membranes.

 

References

  1. Alexanderov,M.T. Osnovy`lazernoi`clinichesqoi`biofotometrii / M.T. Alexanderov. — Sochi: Intermed, 1991. — 87 s.
  2. Amirov, N.B. Sravnitel`naia ocenqa razlichny`kh metodov lazeroterapii pri nespetci-fichesqikh zabolevaniiakh legqikh / N.B. Amirov, S.A. Pigalova, I.I. Kamalov [i dr.] // Lazery` v Povolzh`e: tez. docl. 1-i` Regional`noi` qonf. — Kazan`, 1997, S.49—50.
  3. Bart, B.Ia. Uluchshenieqachestvazhiznibol`ny`khbronhial`noi` astmoi` pri provedenii profilaqtichesqikh qursov vnutrivennoi` lazernoi` terapii v policlinichesqikh usloviiakh / B.Ia. Bart, S.S. Solov`ev, N.V. Kosnova, M.G. Golovqo // Problemy` lazernoi` meditciny`:materialy`IVMezhdunar.qongressa.—M.; Widnoe, 1997. — S.159.
  4. Gamaleia, N.F. K mehanizmu biostimuliatcii. Lazernaia i magnitolazernaia terapiia v meditcine / N.F. Gamaleia, E.D. Shishqo, Iu.V. Ianish [i dr.]. — M., 1987. — S.57—60.
  5. Gorbatenqova, E.A. Fotoreaqtcivatciiafermentov— osnovnoi` mehanizm terapevtiche-sqogodei`stviiagelii`-neonovogolazera / E.A.Gorbatenqova,N.V.Paramonov,I.V.Luq`iashchenqo // Primenenie lazerov v hirurgii i meditcine: materialy` Mezhdunar. simp. — M.: Nauqa, 1989. — S.280.
  6. Eliseenqo, V.I. Nizqoe`nergetichesqie lazery` v mehanizme stimuliatcii nespetcifiche-sqogo immuniteta / V.I. Eliseenqo, V.D. Basqin, N.V. Baliukh // Problemy` lazernoi` meditci-ny`: materialy` IV mezhdunar. qongr. — M.; Widnoe, 1997. — S.151—153.
  7. Illarionov, V.E. Osnovy`lazernoi`terapii/V.E.Illarionov.—M.: Inotekh-progress, 1992. — S.123.
  8. Kozlov, V.I. Lazeroterapiia / V.I. Kozlov, V.A. Bui`lin. — M., 1993.
  9. Korochqin, I.M. Neinvazivnoe primenenie izlucheniia nizqointensivnogo gelii`-neonovogo lazera dlia lecheniia ostry`kh pnevmonii`: metod. reqomendatcii / I.M. Korochqin, G.M. Kapustina, V.L. Naminov. — M., 1989.
  10. Oslopov, V.N. Znachenie membranny`kh narushenii` v razvitii gipertonichesqoi` bolez-ni: dis. ... doqt. med. nauq / V.N. Oslopov. — Kazan`, 1995. — 492 s.
  11. Pluzhniqov, M.S. Osnovny`e puti razvitiia «lazernoi` meditciny`» v nashei` strane / M.S. Pluzhniqov // Novy`e meditcinsqie tekhnologii. — M., 1999. — S.1—5.
  12. Pletnev, S.D. Lazery` v clinichesqoi` meditcine / S.D. Plet-nev. — M.: Meditcina, 1996. — S.482.
  13. Hamitov, R.F. Clinichesqie reqomendatcii po diagnostiqe i lecheniiu vnebol`nichny`kh pnevmonii` u vzrosly`kh: monografiia / R.F. Hamitov, A.A. Wizel`, N.B. Amirov, M.V. Potapova, G.V. Ly`senqo Kazan`, 2011. — 99 s.
  14. Shchegol`qov, A.M. Lazeroterapiia v pul`monologii / A.M. Shchegol`qov, L.M. Cliachqin, V.P. Iaroshenqo, I.L. Cliachqin // Pul`monologiia. — 2000. — № 4. — S.11—17.
  15. Gritten. Laseretmedcin. Introduction / Gritten, P.Franchiman // Rev. med. Liege. — 1987. — Vol. 42, № 6. — Р.213—215.
  16. Keptesz, I. Hypothetical Phisicial Model for Laser Biostimulation / I. Keptesz, M. Fenyo, E. Mester, I. Bathory // Optics and Laser Technology. — 1982. — № 1. — Р.31—32.
  17. Parlato, Y. Superoxide dismutase activiti in the skin of rats irradiqtede by He-Ne laser / Y. Parlato, Y. Cimmino, E. de Vendittis [еt al.] // Experientia. — 1983. — Vol. 39, № 7. — Р.750—751.

 

HELP FOR PRACTITIONER

PDF downloadRole of whole body plethysmography in practice of general practitioner

Rustem I. Shaymuratov, resident of phthisiopulmonology chair, Kazan State Medical University, 420012, Kazan, Butlerova str. 49. russtem@gmail.com.

Olga Yu. Mikhoparova, chief of an office of functional diagnostics of clinical hospital, olga-mihoparova@rambler.ru.

Elvira B. Frolova, assistant to the head physician by a medical part of clinical hospital, frolova.67@mail.ru.

Abstract.This article describes the basic principles and methods of research in respiratory function, especially whole body plethysmography andlung diffusion capacity measurements. Interpretation of the study protocol is described in details. The possibilities of diagnosing obstructive pulmonary diseases are demonstrated in an example of whole body plethysmography study with a bronchodilator.

Key words: whole body plethysmography, lung diffusion capacity, DLCO.

 

References

  1. Rukovodstvo po klinicheskoj fiziologii dyhanija / Pod red. L.L. Shika, N.N. Kanaeva. – L.: Medicina, 1980. – 376 s., il.
  2. Davidovskaja E. I., Manichev I.A., Shherbickij V. G. Spirometrija segodnja: kak ispol'zovat' novye vozmozhnosti i izbezhat' staryh oshibok (chast' I) // Medicina. – 2008. – № 3. – S. – 85-88.
  3. M.A. Grippi. Patofiziologija legkih. – Izd. 2-e, isprav. M.: Izdatel'stvo BINOM, 2008. – 304 s., ill.
  4. Pul'monologija / pod red. A.G. Chuchalina. – 2-e izd., ispr. i dop. – M. : GJeOTAR-Media, 2011. – 336 s. – (Serija «Klinicheskie rekomendacii»).
  5. M.A. Poljanskaja Bodipletizmografija i issledovanie DLCO – metodika provedenija i interpretacija rezul'tatov // Zdorov'e Ukrainy. – 2008. – № 9/1. – S. – 52-53.
  6. Sarkoidoz: Monografija / Pod red. Vizelja A.A. (Serija monografij Rossijskogo respiratornogo obshhestva; Gl. red. Serii Chuchalin A.G.). – M.: Izdatel'skij holding «Atmosfera», 2010. – 416 s., ill.
  7. Ujest Dzh. Patofiziologija organov dyhanija / Per. s angl. pod redakciej A.I. Sinopal'nikova. – M.:BINOM, 2008. – 232 s.

 

REVIEW

PDF downloadUpdate on current therapy of asthma

Majid Sadigh, mD, Department of Internal medicine and Infectious diseases, Saint mary’s Hospital, Waterbury, CT, uSA, Yale-affiliated, e-mail: majid.Sadigh@yale.edu

Jaime P. Moskowitz, mD, Internal medicine Resident, Saint mary’s Hospital, Waterbury, CT, uSA, Yale-affiliated, e-mail: jaimepadavil@gmail.com

Rustem I. Shaymuratov, resident of phthisiopulmonology chair, Kazan State medical university, 420012, Kazan, Butlerova str. 49, e-mail: russtem@gmail.com

He Zhang, mD, PhD, Department of Pulmonary and Critical medicine, Saint mary’s Hospital, Waterbury, CT, uSA, Yale-affiliated, e-mail: He.zhang@stmh.org

Alexander A. Vizel, mD, PhD, Professor of phthisiopulmonology chair, Kazan State medical university, 420012, Kazan, Butlerova str. 49, e-mail: lordara@mail.ru

Abstract. Asthma is a serious health problem and one of the most common causes of morbidity and mortality worldwide. The therapy of asthma has evolved significantly during the last two decades attributing to better understanding of pathogenesis. According to asthma therapy guidelines, inhaled corticosteroids and long acting beta agonist are recommended as the corner stone of moderate to severe persistent asthma therapy. Immunotherapy is recommended as an adjuvant therapy for allergic asthma. Recently, phosphodiesterase 4 inhibitor and bronchiothermoplasty therapy are approved for asthma. We reviewed the systemic side effects of long term use of inhaled corticosteroids, safety of long acting beta2-agonist,clinicalexperienceofimmunotherapyfocusingonanti-IgEtherapyandspecificimmunotherapy, clinical evidence for use of phosphodiesterase 4 inhibitor and bronchiothermoplasty.

Key words: asthma, therapy, inhaled corticosteroids, LABA, PDE4 inhibitor, specific immunotherapy, bronchiothermoplasty.

 

References

  1. The state of asthma in America: Asthma in America survey. (February 9, 2009,   HYPERLINK "http://www.asthmainamerica.com"  http://www.asthmainamerica.com
  2. Expert panel report 3: guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, August 2007. (NIH publication no. 07-4051.) (February 9, 2009,   HYPERLINK "http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf"  http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf
  3. Federal'naja celevaja programma RF «Bronhial'naja astma» na 2011-2015 gody, 2009; Chuchalin A.G. 2000, 2003, 2006; Bilichenko T. N., 1997; Leshhenko I.V., 2001; Emel'janov A.V., Fedoseev G.B., Sergeeva, 2002; Fedoseev G.B., Trofimov V.I., 2006; Knjazheskaja N.P., 2006.
  4. ''Asthma'', M. Parker. Otolaryngol Clin N Am 44 (2011) 667–684
  5. H. Derendorf, R. Nave, A. Drollmann, F. Cerasoli and W. Wurst Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma // Eur Respir J 2006; 28: 1042–1050.
  6. Patrick O Sobande, Carolyn M Kercsmar. Inhaled Corticosteroids in Asthma // Management Respiratory Care May 2008 Vol 53 No 5 625
  7. GINA Report, Global Strategy for Asthma Management and Prevention: Updated 2010. – Url:   HYPERLINK "http://ginasthma.org"  http://ginasthma.org .
  8. Systemic Adverse Effects of Inhaled Corticosteroid Therapy A Systematic Review and Meta-analysis Brian J. Lipworth, MD, FRCPE ARCH INTERN MED/VOL 159, MAY 10, 1999
  9. Ciclesonide, a Novel Inhaled Steroid, Does Not Affect Hypothalamic-Pituitary-Adrenal Axis Function in Patients With Moderate-to-Severe Persistent Asthma Stanley Szefler, MD; Shashank Rohatagi, PhD, MBA; James Williams, MD; Mark Lloyd, BS; Sudeep Kundu, PhD; and Donald Banerji, MD Chest 2005;128;1104-1114
  10. Inhaled Corticosteroids and the Risks of Diabetes Onset and Progression Samy Suissa, PhD Abbas Kezouh, PhD, Pierre Ernst, MD, MSc, The American Journal of Medicine, Vol 123, No 11, November 2010
  11. Anderson GP, Linden A, Rabe KF. Why are long-acting beta-adrenoceptor agonists long acting? // Eur. Respir. J. – 1994. – Vol. 7. – N 3. – P.569–78.
  12. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial R.A. Pauwels, M.R. Sears, M. Campbell, C. Villasantez, S. Huang, A. Lindh, W. Petermann, M. Aubier, G. Schwabe, T. Bengtsson, on behalf of the RELIEF Study investigators Eur Respir J 2003; 22: 787–794
  13. The controversy over long-acting beta agonists: Examining the evidence David M. Lang, Md Cleveland Clinic Journal Of Medicine Volume 73 Number 11 November 2006 973-992
  14. The Safety of Long-Acting β-Agonists among Patients with Asthma Using Inhaled Corticosteroids Systematic Review and Metaanalysis Roman Jaeschke, Paul M. O'Byrne, Filip Mejza, Parameswaran Nair, Wiktoria Leśniak, Jan Brożek, Lehana Thabane, Ji Cheng, Holger J. Schünemann, Malcolm R. Sears and Gordon Guyatt. Am. J. Respir. Crit. Care Med. November 15, 2008 vol. 178 no. 10 1009-1016
  15. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Greenstone IR, Ni Chroinin MN, Masse V, Danish A, Magdalinos H, Zhang X, Ducharme FM. Update in Cochrane Database Syst Rev. 2010;(4):CD005533.
  16. The FDA and Safe Use of Long-Acting Beta-Agonists in the Treatment of Asthma Badrul A. Chowdhury, M.D., Ph.D., and Gerald Dal Pan, M.D., M.H.S.
  17. Long-acting Beta-Agonists with and without Inhaled Corticosteroids and Catastrophic Asthma Events Shelley R. Salpeter, MD, FACP,a,b Andrew J. Wall, MD,a,b Nicholas S. Buckleyc The American Journal of Medicine (2010) 123, 322-328
  18. Anti-IgE for chronic asthma in adults and children (Review) Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2008, Issue 4
  19. Immunoglobulin E Receptor Signaling and Asthma*Published, JBC Papers in Press, July 28, 2011, DOI 10.1074/jbc.R110.205104 Lawren C. Wu From the Department of Immunology, Genentech, Incorporated, South San Francisco, California 94080 The Journal Of Biological Chemistry Vol. 286, NO. 38, pp. 32891–32897, September 23, 2011
  20. Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects Gail M Gauvreau, Louis-Philippe Boulet2, Christine Schmid-Wirlitsch3, Johanne Cote2, MyLinh Duong1, Kieran J Killian1, Joanne Milot2, Francine Deschesnes2, Tara Strinich1, Richard M Watson1, Dirk Bredenbroker3 and Paul M O’Byrne1 Gauvreau et al. Respiratory Research 2011, 12:140
  21. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005; 365: 167–75. Brian J Lipworth,  Department of Medicine and Therapeutics, Asthma and Allergy Research Group
  22. Improvement of Therapeutic Index of Phosphodiesterase Type IV Inhibitors as Anti-Asthmatics Euikyung Kim,a,c,* Hyung-Ok Chun,a Sung-Hak Jung,a Jong Hoon Kim,b Jae-Mok Lee,b Byung-Chul Suh,b Myung Xik Xiangb,d and Chung K. Rheeb,d,* Bioorg. Med. Chem. Lett. 13 (2003) 2355–2358
  23. Allergen-specific immunotherapy, William Moote et al. Allergy, Asthma & Clinical Immunology 2011, 7(Suppl 1):S5
  24. A Review of Allergy and Allergen Specific Immunotherapy Katayoon Bidad, Mohammad Hossein Nicknam, and Reza Farid Iran J Allergy Asthma Immunol March 2011; 10(1): 1-9
  25. Injection Allergen Immunotherapy for asthma. Abramson et al. Cochrane Database of Systematic Reviews 2010, Issue 8. Art. No.: CD001186. DOI: 10.1002/14651858.CD001186.pub2.
  26. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized clinical trials using the Cochrane Collaboration method.  Calamita Z, Saconato H, Pela AB, Atallah AN Allergy 2006, 61:1162-72.
  27. Systemic Adverse Reaction to Specific Immunotherapy Alsamarai AM, Ahmad Alobaidi AH, Alwan AM, Abdulaziz ZH and Alsamarai Z et al. J Aller Ther 2011, 2:2
  28. Asthma Control during the Year after Bronchial Thermoplasty. Cox et al. N Engl J Med 2007;356:1327-37.
  29. Safety and Efficacy of Bronchial Thermoplasty in Symptomatic, Severe Asthma. Pavord et al. Am J Respir Crit Care Med. Vol 176. pp 1185–1191, 2007
  30. Effectiveness and Safety of Bronchial Thermoplasty in the Treatment of Severe Asthma, Castro et al Am J Respir Crit Care Med,Vol 181. pp 116–124, 2010)
  31. Long-term (5 year) safety of bronchial thermoplasty: Asthma Intervention Research (AIR) trial, Thomson et al. BMC Pulmonary Medicine 2011, 11:8

 

PDF downloadSarcoidosis: the possibility of spontaneous remission

Irina Yu. Vizel cand. sci. med. phthisiopulmonology chair, Kazan State Medical University, 420012, Kazan, Butlerova str. 49.

Abstract. A review of clinical studies and examples on the possibility of spontaneous remission of sarcoidosis was presented. Regression of sarcoidosis occurred most often in foreign hospitals, where the contact with patients with tuberculosis and other infectious diseases is excluded, which can trigger granulomatosis. The possibility of spontaneous remission does not negate the purpose of active treatment according to vital indications.

Key words: sarcoidosis, prognosis, remission, treatment.

 

References

  1. Borisov S.E., Kupavceva E.A. Lechenie sarkoidoza // V sb.: Sbornik nauchnyh trudov, posvjashhjonnyj 80–letiju instituta. M.:NII ftiziopul'monologii MMA im.I.M.Sechenova, 1998: 62–68.
  2. Borisov S.E., Kupavceva E.A., Bogorodskaja E.M. i dr. Diagnostika i lechenie sarkoidoza v uslovijah specializirovannogo centra // Pul'monologija, 2001. 11-j Nacional'nyj kongress po boleznjam organov dyhanija: Sbornik rezjume. Ref № XLIII.2.: 225.
  3. Burova N.Ju., Tuganova V.E. Otdalennye rezul'taty lechenija bol'nyh sarkoidozom organov dyhanija // Probl.tub. 1982; 4: 46–49.
  4. Vizel' A.A., Nasretdinova G.R., Islamova L.V., Vizel' E.A. Ocenka jeffektivnosti razlichnyh rezhimov lechenija bol'nyh vnov' vyjavlennym sarkoidozom v Respublike Tatarstan // Probl. tub. 2006; 4: 19–23.
  5. Vizel' I.Ju., Vizel' A.A. Itogi odnogodichnogo nabljudenija bol'nyh s gistologicheski verificirovannym sarkoidozom // Kazanskij med.zh. 2010; XCI (6): 724-729.
  6. Garmash Ju.Ju. Rol' social'no-professional'nyh faktorov v formirovanii hronicheskih form sarkoidoza organov dyhanija i ego recidivov // Probl. tub. 2005; 8: 54-57.
  7. Kevorkov N.N., Gorovic G.A., Bahmet'ev S.A. Likopid v kompleksnom immunokorrigirujushhem lechenii bol'nyh sarkoidozom ljogkih i vnutrigrudnyh limfaticheskih uzlov // Ter.arhiv. 2002; 3: 55–58.
  8. Ozerova L.V. Sarkoidoz: diagnostika, klinika, techenie i lechenie // Probl.tub. 1995; 4: 51–54.
  9. Ozerova L.V., Romanov V.V., Zajceva I.P. i dr. Atipichnye i neblagoprijatnye varianty techenija sarkoidoza // Probl.tub. 2001; 7: 42–45.
  10. Rabuhin A.E., Dobrohotova M.N., Tonitrova N.S. Sarkoidoz. M.:Medicina, 1975: 175 s.
  11. Sanickaja L.N., Zubkov A.A., Adamovich V.N. Osobennosti kliniki i techenija sarkoidoza 1 stadii // V sb. Differencial'naja diagnostika sarkoidoza i tuberkuleza legkih. Pod red. V.N.Adamovicha. M., 1998: 52-58.
  12. Sarkoidoz / Pod red. A.G.Homenko, O.Shvajgera. SSSR–VNR. M.:Medicina, 1982: 296 s.
  13. Tjuhtin N.S., Ushakova M.F., Stogova N.A., Grishaeva L. N. Dispansernoe nabljudenie bol'nyh sarkoidozom // Nauchno-medicinskij vestnik Central'nogo Chernozem'ja. 2002; 10: 14-18.
  14. Homenko A.G. Sarkoidoz organov dyhanija (diagnostika i terapija) // Klin.med. ––1983. 12: 129–134.
  15. Homenko A.G., Gedymin L.E., Ozerova L.V. i dr. K jetiologii i patogenezu sarkoidoza // Pul'monologija. 1996. 6 Nacional'nyj kongress po boleznjam organov dyhanija. Novosibirsk,. Ref. № 0574. S. 154.
  16. Homenko A.G., Erohin V.V., Filippov V.P. i dr. Sarkoidoz kak sistemnyj granulematoz. M.:Medicina, 1999: 39 s.
  17. Shkunov A.N. Dispansernoe nabljudenie i jeffektivnost' lechenija bol'nyh sarkoidozom // Probl.tub. 1995; 1: 56.
  18. Shmelev E.I. Sarkoidoz // Atmosfera: Pul'monologija i allergologija. 2004; 2 (13): 3–10.
  19. Arriero J.M., Signes-Costa J., Chiner E., Marco J. Spontaneous remission of pulmonary and splenic lesions in sarcoidosis // Radiography. 2000; 6(4): 303–306.
  20. Asada K., Chida K. Prognosis and prognostic factors of sarcoidosis in Japan // Nippon Rinsho. 2002; 60(9): 1839–1844.
  21. Baughman R.P., Lynch J.P. Difficult treatment issues in sarcoidosis // J. Intern. Med. 2003; 253(1): 41-45.
  22. Baughman R.P., Sharma O.P., Lynch J.P. 3rd. Sarcoidosis: is therapy effective? // Semin. Respir. Infect. 1998; 13(3): 255–273.
  23. Cemlyn-Jones J., Gamboa F., Teixeira L., Bernardo J., Robalo Cordeiro C. Sarcoidosis: a less common presentation // Rev. Port. Pneumol. 2009; 15(3): 543-552.
  24. Drent M., Jacobs J.A., de Vries J. et al. Does the cellular bronchoalveolar lavage fluid profile reflect the severity of sarcoidosis? // Eur.Respir.J. 1999; 13(6): 1338–1344.
  25. Fanburg B.L. Drug therapy reviews: treatment of sarcoidosis // Am. J. Hosp. Pharm. 1979; 36(3): 351-354.
  26. Gibson G.J. Sarcoidosis: old and new treatments // Thorax. 2001; 56(5): 336–339.
  27. Inaba H., Suzuki S., Shigematsu S., Kobayashi S., Nishio S., Hashizume K. Spontaneous remission of diabetes insipidus due to CNS sarcoidosis // Intern Med. 2009; 48(4):225-229.
  28. Israel H.L., Sperber M., Steiner R.M. Course of chronic hilar sarcoidosis in relation to markers of granulomatous activity // Invest.Radiol. 1983; 18(1): 1–5.
  29. Johnson A.K., Johnson J.M., Ames E., Filippi C. Spontaneous clinical and radiological resolution of vertebral sarcoidosis: a case report // Spine (Phila Pa 1976). 2012; 37(6): E414-416.
  30. Judson M.A. Clinical aspects of pulmonary sarcoidosis // J. S. C. Med. Assoc. 2000; 96(1): 9–17.
  31. Kaneko M., Tomioka H., Kaneda T., Kubot M., Tani S., Fujii H., Katsuyama E., Okazaki M. Value of 18F-fluorodeoxyglucose-PET in the diagonosis and monitoring of pulmonary sarcoidosis: a case report // Nihon Kokyuki Gakkai Zasshi. 2008; 46(6): 505-509.
  32. Leung W.K., Lei K.I., Yim A. et al. Sarcoidosis in a Hong Kong Chinese woman // Hong Kong Med. J. 1998; 4(3): 333–336.
  33. Londner C., Zendah I., Freynet O., Carton Z., Dion G., Nunes H., Valeyre D. Treatment of sarcoidosis // Rev. Med. Interne. 2011; 32(2): 109-113.
  34. Margery J., Bonnichon A., Vaylet F., Bredin C., L'Her P., de Revel T. Spontaneous regression of hepatic and splenic involvements during sarcoidosis // Rev Pneumol Clin. 2007; 63(2): 109-110.
  35. McCullough P.C., McCullough A.E. Nodular sarcoidosis // N. Engl. J. Med. 2002. Vol. 346(25): 1970.
  36. Mihailovic-Vucinic V., Jovanovic D. Pulmonary sarcoidosis // Clin. Chest Med. 2008 ; 29(3): 459-73, viii-ix.
  37. Murakami K., Tamada T., Abe K., Nara M., Hisata S., Mitsuishi Y., Muramatsu S., Gomi K., Ebina M., Nukiwa T. Rapid improvement of osseous sarcoidosis after the treatment of pulmonary aspergillosis by itraconazole // Sarcoidosis Vasc. Diffuse Lung Dis. 2011; 28(1): 75-78.
  38. Newman L.S., Rose C.S., Maier L.A. Sarcoidosis // N.Engl.J.Med. 1997; 336(17): 1224–1234.
  39. Pavlovic-Popovic Z., Djuric B. Sarcoidosis: ten year experience // Abstract book of 7th WASOG Congress in Stockholm June 16-19 2002. Abstr. N 24.
  40. Pettersson T. Rheumatic features of sarcoidosis // Curr.Opin.Rheumatol. 1998; 10(1): P.73–78.
  41. Pietinalho A., Ohmichi M., Lofroos A.B. et al. The prognosis of pulmonary sarcoidosis in Finland and Hokkaido, Japan: A comparative five-year study of biopsy-proven cases // Sarcoidosis Vasc. Diffuse Lung Dis. 2000; 17(2): 158–166.
  42. Romer F.K.. Presentation of sarcoidosis and outcome of pulmonary changes // Dan. Med. Bull. 1982; 29(1): 27–37.
  43. Schoni M.H. On the edge of facts and hypotheses // Respiration. 2000; 67(2): 135–136.
  44. Siltzbach L.E., James D.G., Neville E., Turiaf J., Battesti J.P., Sharma O.P., Hosoda Y., Mikami R., Odaka M. Course and prognosis of sarcoidosis around the world // Am. J. Med. 1974; 57(6): 847-852.
  45. Sugie T., Hashimoto N., Iwai K. Clinical and autopsy studies on prognosis of sarcoidosis // Nippon Rinsho. 1994; 52(6): 1567–1570.
  46. Takesh M., Haberkorn U., Strauss L.G., Roumia S., Dimitrakopoulou-Strauss A. Incidental detection and monitoring of spontaneous recovery of sarcoidosis via fluorine-18-fluoroethyl-choline positron emission tomography/computed tomography // Hell. J. Nucl. Med. 2012; 15(1): 63-65.

 

PDF downloadAcute lung injury: the definition, pathogenesis, animal models and the role of mesenchymal stem cells in experimental treatment

K.S. Voytkovskaya, student of Faculty of Basic Medicine MSU, Russia, 119192, Moscow, Lomonosovskiy prospect, 31 corp. 5, ksusha-voi@yandex.ru.

A.L. Cherniaev, MD, professor, head of pathology department FSI “Pulmonary Research Institute” Federal Medical and Biological Agency of Russia, Russia, 105077, Moscow, 11th Parkovaya street, 32, cheral12@gmail.com.

Abstract. Acute lung injury (ALI) is a clinical syndrome with definite histological criteria of lung structure lesion. ALI is widespread in clinical practice and has a high lethality. In this article we describe the definition, clinics, etiology, pathogenesis, animal models of ALI. In this review we describe a role of mesenchymal stem cells (MSC) in treatment of experimental ALI, induced by lipopolysaccharide.

Key words: acute lung injury, experiment, lipopolysaccharide, mesenchymal stem cells.

 

References

  1. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults / Lancet - 1967; - V.2, 319-323.
  2. Ware LB., Matthay AM The Acute Respiratory Distress Syndrome / N Engl J Med - 2000; - V.342, 1334-1349.
  3. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination / Am. J. Respir. Crit. Care Med. - 1994; - V.149, 818-24.
  4. Obshherossijskaja obshhestvennaja organizacija «Federacija anesteziologov i reanimatologov» Protokol vedenija bol'nyh. Diagnostika i intensivnaja terapija sindroma ostrogo povrezhdenija legkih i ostrogo respiratornogo distress-sindroma. Prinjat  na X-m S#ezde anesteziologov i reanimatologov 21 sentjabrja 2006 goda (http://far.org.ru/Data/farDisk/Protokoly/2.htm).
  5. Gordon D. Rubenfeld, Ellen Caldwell, Eve Peabody et al. Incidence and Outcomes of Acute Lung Injury / N Engl J Med. - 2005; V.353, 1685-1693.
  6. Brun-Buisson C, Minelli C, Bertolini G, et al. Epidemiology and outcome of acute lung injury in European intensive care units. Results from the ALIVE study / Intensive Care Med.-  2004; - V. 30, 51–61.
  7. American Thoracic Society. Round Table Conference: acute lung injury / Am J Respir Crit Care Med - 1998; - V.158, 675–9.
  8. Looney MR, Nguyen JX, Hu Y et al. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury / J Clin Invest. - 2009 Nov; - V.119 N.11, 3450-61.
  9. Wiener-Kronish JP, Albertine KH, Matthay MA Differential responses of the endothelial and epithelial barriers of the lung in sheep to Escherichia coli endotoxin / J Clin Invest.  -1991 Sep; - V.88 N.3, 864-75.
  10. Albertine KH, Soulier MF, Wang Z et al Fas and Fas Ligand Are Up-Regulated in Pulmonary Edema Fluid and Lung Tissue of Patients with Acute Lung Injury and the Acute Respiratory Distress Syndrome / Am J Pathol. - 2002 November; - V.161 N.5, 1783–1796.
  11. Zemans RL, Colgan SP, Downey GP Transepithelial migration of neutrophils: mechanisms and implications for acute lung injury / Am J Respir Cell Mol Biol. - 2009 May; - V.40 N.5, 519-35.
  12. Modelska K, Pittet JF, Folkesson HG et al. Acid-induced lung injury: protective effect of anti-interleukin-8 pretreatment on alveolar epithelial barrier function in rabbits / Am J Respir Crit Care Med - 1999; - V.160, 1450-1456.
  13. Lewis JF, Jobe AH. Surfactant and the adult respiratory distress syndrome / Am Rev Respir Dis - 1993; - V.147, 218-233 [Erratum, Rev Respir Dis - 1993; - V.147, 1068.].
  14. Bitterman PB. Pathogenesis of fibrosis in acute lung injury / Am J Med - 1992; - V.92, 39S-43S.
  15. Gustavo Matute-Bello, Charles W. Frevert, and Thomas R. Martin Animal models of acute lung injury / Am J Physiol Lung Cell Mol Physiol. - 2008 September; - V.295 N.3, L379–L399.
  16. Lee JW, Fang X, Gupta N, et al. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin–induced acute lung injury in the ex vivo perfused human lung / Proc Natl Acad Sci USA.-  2009; - V.106, 16357–62.
  17. Schromm AB, Brandenburg K, Loppnow H et al. Biological activities of lipopolysaccharides are determined by the shape of their lipid A portion / Eur J Biochem. -  2000 Apr; - V.267 N.7, 2008-13.
  18. Kuida H, Hinshaw LB, Gilbert RP, Visscher MB. Effect of gram-negative endotoxin on pulmonary circulation / Am J Physiol  - 1958 – V.192, 335–344.
  19. Komuro T, Yomota C, Kimura T, Galanos C. Comparison of R- and S-form lipopolysaccharides fractionated from Escherichia coli UKT-B lipopolysaccharide in pyrogen and Limulus tests / FEMS Microbiol Lett. - 1989 Jul 1; - V.51 N.1, 79-83
  20. Tapping RI, Akashi S, Miyake K et al. Toll-like receptor 4, but not toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides / J Immunol. - 2000 Nov 15; - V.165 N.10, 5780-7.
  21. S. Akashi, H. Ogata, F. Kirikae et al. Regulatory roles for CD14 and phosphatidylinositol in the signaling via toll-like receptor 4-MD-2 / Biochem. Biophys. Res. Commun. – 2000; – V. 268, 172-177.
  22. http://en.wikipedia.org/wiki/File:Toll-like_receptor_pathways_revised.jpg
  23. Y. Nagai, S. Akashi, M. Nagafuku et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution / Nat. Immunol. – 2002; – V. 3, 667-672.
  24. Takeda K., Kaisho T., Akira S. Toll-like receptors / Annu. Rev. Immunol. – 2003; – V. 21, 335-376.
  25. Basu S., Fenton M. J. Toll-like receptors: function and roles in lung disease / Am. J. Physiol. Lung Cell Mol. Physiol. – 2004; - V. 286, L887-L892.
  26. Muzio M., Ni J., Feng P., Dixit V. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling / Science. — 1997; — Vol. 278 (5343). — P. 1612–1617.
  27. Guillot L., Medjane S., Le-Barillec K., et al. Response of Human Pulmonary Epithelial Cells to Lipopolysaccharide Involves Toll-like Receptor 4 (TLR4)-dependent Signaling Pathways. Evidence for an intracellular compartmentalization of TLR4 / J. Biol. Chem. – 2004; - V. 279,  2712-2718.
  28. Meyrick V., Brigham K. L. Acute effects of E. coli endotoxin on the pulmonary microcirculation of anesthetized sheep: structure-function relationships / Lab. Invest.— 1983. — Vol. 48; — P. 458—470.
  29. Williams JH, Patel SK, Hatakeyama D et al. Activated pulmonary vascular neutrophils as early mediators of endotoxin-induced lung inflammation / Am J Respir Cell Mol Biol. – 1993; - V.8, 134-144.
  30. Gordon T, Harkema JR. Effect of inhaled endotoxin on intraepithelial mucosubstances in F344 rat nasal and tracheobronchial airways / Am J Respir Cell Mol Biol. – 1994; - V.10, 177-183.
  31. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells The International Society for Cellular Therapy position statement / Cytotherapy - 2006; - V.8, 315-317.
  32. Baddoo M, Hill K, Wilkinson R, et al. Characterization of mesenchymal stem cells isolated from murine bone marrow by negative selection / J Cell Biochem – 2003; - V.89, 1235-1249
  33. Ramalho-Santos M, Yoon S, Matsuzaki Y, et al, "Stemness": transcriptional profiling of embryonic and adult stem cells / Science - 2002; - 298, 597-600
  34. Cognet PA, Minguell JJ Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells / J Cell Physiol – 1999; - V.181, 67-73
  35. Muguruma Y, Yahata T, Miyatake H, et al. Reconstitution of the functional human hematopoietic microenvironment derived from human mesenchymal stem cells in the murine bone marrow compartment / Blood - 2006; - V.107, 1878-1887.
  36. Honczarenko M, Le Y, Swierkowski M, et al. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors / Stem Cells - 2006; - V.24, 1030-1041.
  37. Lapidot T, Dar A, Kollet O. How do stem cells find their way home? / Blood - 2005; - V.106, 1901–1910.
  38. Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide / Blood - 2003; - V.101, 3722-3729.
  39. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli / Blood - 2002; - V.99, 3838-3843.
  40. Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions / Blood - 2006; - V.107, 367-372.
  41. Neuringer IP, Randell SH. Lung stem cell update: promise and controversy / Monaldi Arch Chest Dis – 2006; - V. 65, 47-51.
  42. Kotton DN, Ma BY, Cardoso WV, et al. Bone marrow-derived cells as progenitors of lung alveolar epithelium / Development. - 2001; - V.128, 5181–8
  43. Kotton DN, Fabian AJ, Mulligan RC. Failure of bone marrow to reconstitute lung epithelium / Am J Respir Cell Mol Biol. - 2005; - V.33, 328–34.
  44. Zhen G, Xue Z, Zhao J et al. Mesenchymal stem cell transplantation increases expression of vascular endothelial growth factor in papain-induced emphysematous lungs and inhibits apoptosis of lung cells / Cytotherapy. - 2010 Sep; - V.12 N.5, 605-14.
  45. Rojas M, Xu J, Woods CR, et al. Bone marrow-derived mesenchymal stem cells in repair of the injured lung / Am J Respir Cell Mol Biol – 2005; - V.33, 145-52.
  46. Gupta N, Su X, Popov B, et al. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice / J Immunol – 2007; - V.179, 1855-63.
  47. Németh K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production / Nat Med. - 2009 Jan; - V.15 N.1, 42-9 [Erratum in Nat Med. - 2009 Apr; -  V.15 N.4, 462.].
  48. van Haaften T, Byrne R, Bonnet S, et al. Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats / Am J Respir Crit Care Med. - 2009; - V.180, 1131–42.
  49. Aslam M, Baveja R, Liang OD, et al. Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease / Am J Respir Crit Care Med. - 2009; - V.180, 1122–30.
  50. Lee JW, Fang X, Gupta N, et al. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin–induced acute lung injury in the ex vivo perfused human lung / Proc Natl Acad Sci USA.-  2009; - V.106, 16357–62.

 

PDF downloadIn memory of Nikolay Grigoryevich Sokolov

A.A. Vizel